FDA approves Merck’s KEYTRUDA® (pembrolizumab) for gastroesophageal junction cancer
Merck announced the FDA has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1. September 22, 2017